leisure time -WSS

leisure time

author：entertainment 2025-09-28 08:53:38 - browse：26845

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

knowledge

entertainment

WSS

The Affordable Care Act has saved billions in health care costs

Medicare drug price negotiation legal challenge met with skepticism

Wegovy leads to weight loss. Can it treat depression, too?

The science behind Janet Jackson's pregnancy at 49

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Death of patient in Alzheimer’s trial raises question of possible risks

hotspot

leisure time

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

WATCH: Why do fingernails fall off when they're damaged?

Medical records are filled with copy

Biogen walks away from Aduhelm, years after polarizing approval

Virginia high school admissions case could be legal follow

Pancreatic cancer early detection could be helped by AI

Anesthesiologist group: stop taking Ozempic before surgery

Vertex non

Malaria cases in Florida and Texas: Here’s what you need to know

Boston competes with Raleigh

hotspot

What would happen to your eyes if you looked at the solar eclipse?

Why Medicare shouldn’t cover every FDA

#NeedHerScience: shining a light on gender disparities in medicine

Venture capital firm's plans to take over Akron hospital face hurdles

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Colonoscopy at 40? Study finds a possible benefit

entertainment

focus

entertainment

leisure time